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The content of islet amyloid polypeptide (IAPP) in isolated rat pancreatic islets was determined by a radioimmunoassay. Reverse-phase high-per- 
formance liquid chromatography analysis revealed that a main peak of IAPP immunoreactivity in the extracts from the islets corresponded to 
a synthetic rat IAPP. Secretion of IAPP from the cells is regulated by the extracellular glucose concentration. Thus, IAPP may be a novel regulator 
for glucose homeostasis and changes in the secretion perhaps relate to insular amyloid deposits and impaired glucose tolerance in type 2 diabetes 
mellitus. 
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1. INTRODUCTION 
In type 2 (non-insulin dependent) diabetes mellitus, 
the most significant pathological change in pancreatic 
islets is amyloid deposits [I]. In diabetic macaques, islet 
amyloid deposition increases along with the degree of 
reduction in insulin secretion, accompanied by an in- 
crease in glucose intolerance [2]. In human type 2 
diabetes mellitus, the extent of islet amyloid deposition 
increases with increase in the clinical severity [3]. IAPP, 
also termed amylin, a major component of islet 
amyloid, is a 37 amino acid peptide [4,5]. IAPP seems 
to be a natural occurence in pancreatic B-cells, as deter- 
mined immunohistochemically [6] and by an analysis of 
human genomic DNA encoding IAPP [7]. Gene 
analysis using cDNA cloned from a human insulinoma 
cDNA library revealed that a cDNA encoding IAPP 
contained an open reading frame encoding precursors 
with a typical signal peptide [8]. To investigate possible 
roles of IAPP in functions of the endocrine pancreas 
and the development of type 2 diabetes mellitus, we 
measured the content of IAPP in isolated rat pancreatic 
islets by an RIA which we developed ourselves, analyz- 
ed IAPP immunoreactivity of the extracts from the 
islets by reverse-phase HPLC and examined the 
mechanisms underlying the secretion of this peptide in 
the islet cells. 
amino acid sequence was evaluated by computer programs [g-11]. 
Since the region, Ala&Va117, has the highest antigenicity value, we 
proposed to raise an antiserum against IAPP by immunization of 
oligopeptides consisting of the region. Oligopeptide (R93) was 
assembled automatically by a solid-phase technique, using a 430A 
Peptide Synthesizer (Applied Biosystems Inc., Foster City, CA.). 
Reverse-phase HPLC analysis on a Nucleosil SCis column (4 mm x 15 
cm) (M. Nagel GmbH) indicated that R93 had a purity of 100%. R93 
was linked by glutaraldehyde through the N-terminus to hemocyanin 
keyhole limpet (Calbiochem). The conjugate emulsified with com- 
plete Freund’s adjuvant was given to New Zealand white rabbit. Im- 
munization was repeated every 2 weeks and sera were obtained 7 days 
after the third, fourth and fifth immunizations. 
2.2. Preparation of the tracer and the RIA procedure 
N-tyrosinated R93 radiolabeled with iz51 (New England Nuclear) 
using lactoperoxidase (Sigma Chemical) and purified on a Sephadex 
G-25 column was used as a tracer. The method of the RIA was similar 
to that used for somatostatin [12]. In brief, the diluent for reagents 
was 0.1% gelatin made up in 0.01 M phosphate/O. 14 M NaCY0.25 M 
ethylenedinitrilotetraacetic acid disodium, pH 7.4. The reaction mix- 
tures, the antiserum, standard solution or unknown samples, human 
serum stripped of its peptide by dextran-coated charcoal and tracer 
(approximately 10 000 cpm), were incubated at 4°C for 48 h and the 
free and bound peptides were separated by dextran-coated charcoal. 
Radioactivity of the bound labeled peptide was determined in an 
autogamma counter. R93, N-tyrosinated R93, human insulin (Ac- 
trapid human insulin, Novo Ind.), rat insulin (Novo Ind.), glucagon, 
somatostatin and human and rat calcitonin gene-related peptide (Pep- 
tide Institute, Osaka, Japan) were used to test the cross-reactivity. 
2.3. Measurement of IAPP content in rat pancreatic islets 
2. MATERIALS AND METHODS 
2.1. Immunogen preparation and immunization 
The hydropathy and antigenicity of human IAPP along with its 
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Fed male Sprague-Dawley rats weighing 300 g were anesthetized 
with sodium pentobarbital and the pancreatic islets were isolated by 
a modification of the method described earlier [13]. The islets were 
homogenized in 70% formic acid by sonication. The formic acid was 
removed to near dryness with a vaporizer and the extracts were 
lyophylized. Just before the assay, the extracts were dissolved in 0.2 
N acetic acid, diluted in the assay buffer and adjusted to pH with 
NaOH. The extracts were measured for IAPP-like substance by the 
RIA. 
Abbreviations: IAPP, islet amyloid polypeptide; RIA, radioim- 
munoassay; HPLC, high-performance liquid chromatography 
2.4. Analysis of immunoreactive substance by reverse-phase HPLC 
According to the previously described amino acid sequence, rat 
IAPP was assembled automatically by a solid-phase technique. This 
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peptide was analyzed by reverse-phase HPLC on a TSK gel ODS-12OT 
column (4.6 mm id x 25cm) (Tosoh, Tokyo, Japan) using a linear gra- 
dient from 20 to 80% acetonitrile containing 0.05% trifluroacetic acid 
throughout and the elution profile was monitored at 220 nm. The ex- 
tracts of 300 isolated rat pancreatic islets first partially purified by 
Passage through a Gs Sep Pak (Waters Associates, Melbourne, 
Australia) were analyzed by reverse-phase HPLC. The flow rate was 
0.5 ml/min and fractions were collected every minute. Each fraction 
lyophilized and reconstituted was measured for IAPP-like substance, 
using the RIA. 
(a) 
human insulin 
rat insulin 
glucagon 
somatostatin 
human CGRP 
rat CGRP 
2.5. Secretion from pancreatic islets 
Isolated rat pancreatic islets, 300-400, preincubated in 1 ml i<rebs- 
Ringer bicarbonate buffer, pH 7.4, containing 1 g/l bovine serum 
albumin (RIA grade fraction V: Sigma) and 500 kallikrein inhibiting 
units/ml aprotinin (Bayer, Osaka, Japan) and 2.8 mM glucose were 
incubated for 30 or 60 min in 1 ml of the medium containing 2.8 or 
16.7 mM glucose under 95% 02-5% CO2 at 37°C [15]. IAPP-like 
substance in the medium was assayed by the RIA and insulin was 
measured by RIA using an insulin assay kit (Eiken Chemical, Tokyo, 
Japan). 
Student’s t-test was used for statistical analysis. 
3. RESULTS AND DISCUSSION 
As shown in fig. la, the binding of the tracer with the 
antiserum was inhibited by adding R93, and the 
unlabeled N-tyrosinated R93 and the inhibition was 
dose-dependent. With the antiserum at a final dilution 
of 1:8000 and 10 000 cpm of the tracer, the minimum 
detectable dose was 70 fmol/tube. Intra and interassay 
coefficients of variation were 4.2% and 5.5%, respec- 
tively (assay of identical sample containing 1 pmol/tube 
in five replicates in one assay). Human and rat insulin, 
glucagon and somatostatin, and human and rat 
calcitonin gene-related peptide did not interfere with 
the binding of the tracer with R93-2, thereby indicating 
that this radioimmunoassay is specific for rat IAPP. 
11/11* n=8 
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Since the measured concentrations of IAPP im- 
munoreactivity in extracts from isolated rat pancreatic 
islets fell linearly with dilutions (fig.lb), the material 
assayed is indistinguishable immunologically from this 
peptide. In analysis of the extracts by reverse-phase 
HPLC, the main peak of IAPP immunoreactivity cor- 
responded to the synthetic rat IAPP (fig.2). These find- 
ings strongly suggest that the substance measured by the 
RIA is identified with rat IAPP. The concentration of 
IAPP-like substance is 233.6 f 16.2 fmol/islet (n = 8). 
The presence of IAPP in the islet cells was also confirm- 
ed by an immunohistochemical study using the an- 
tiserum (data not shown), compatible with a previous 
report that IAPP immunoreactive cells were present in 
the islet of cat, dog, mouse and rat. Leffert et al. 
reported that human and rat IAPP differ in 6 of the 37 
residues, all within the 18-29 region [14]. Because the 
8-17 region used for production of our antiserum is 
homologous to the region of rat IAPP, the antiserum 
recognized rat IAPP. 
Fig. 1. Development of RIA, using a specific antiserum for IAPP and 
determination of IAPP-like substances in extracts of normal rat 
pancreatic islets. a: Competitive inhibition of the antiserum tracer 
binding by various peptides. b: Amounts of IAPP-like substance 
determined as a function of the dilution of rat pancreatic islet 
extracts. 
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In the analysis by reverse-phase HPLC, two small 
peaks of IAPP immunoreactivity were observed and 
Fig.2. Analysis of the extracts from isolated rat pancreatic islets by 
reverse-phase HPLC on a TSK gel ODS-12OT column. Closed triangle 
did not correspond to the synthetic rat IAPP. At the indicates retention time of a synthetic rat IAPP. 
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Fig.3. Secretion of IAPP-like substance and insulin from isolated rat 
pancreatic islets incubated for 30 min (a) or 60 min (b) in the presence 
of 2.8 or 16.7 mM glucose. Mean + SEM for IAPP-like substance 
(a) and insulin release (0) are expressed in fmol/islet and &J/islet, 
respectively. Numbers of observations are shown in parentheses. 
*P<O.Ol; compared with the release in the presence of 2.8 mM 
glucose. 
present time we have no precise information regarding 
the molecular basis of the substances eluted in these 
fractions. As the substanties reacted with a specific an- 
tiserum for IAPP, they are peptides related to IAPP, a 
precursor and a degraded peptide of IAPP. This 
hypothesis is supported by isolation of cDNAs en- 
coding rat IAPP from an islet cDNA library and iden- 
tification of a 0.9 kb mRNA encoding a 93 amino acid 
precursor that is proteolyzed to yield the final IAPP 
product [14]. Also, an immunohistochemical study in- 
dicated that IAPP immunoreactivity was found in the 
secretory granules of B-cells and in electron-dense 
regions of some lysosomal or lipofuscin bodies, sug- 
gesting partial degradation of IAPP in the cells [15]. 
As shown in fig.3, an IAPP-like substance was 
secreted from isolated rat pancreatic islets incubated in 
Krebs-Ringer bicarbonate buffer in the presence of 16.7 
mM glucose. The secretion increased along with the 
duration of the incubation time. This is the first 
evidence that IAPP was co-secreted with insulin from 
the pancreatic islet cells and the secretion was regulated 
by glucose, the most important physiological stimulant 
of insulin secretion. IAPP immunoreactivity was shown 
to be localized in the outer lucent compartment of the 
B-cell secretory granule by an immunohistochemical 
study using an A-gold labeling technique [6]. A gene 
analysis using cDNA cloned from a human insulinoma 
cDNA library revealed that a cDNA encoding IAPP 
contained an open reading frame encoding a precursor 
having a typical signal peptide [8]. Also, sequence 
analysis of cDNA encoding rat IAPP showed that a 0.9 
kb mRNA encoded a 93 amino acid precursor and the 
amino-terminal domain was hydrophobic and consis- 
tent with a signal sequence in a secreted protein [14]. 
The presence of a sequence with the properties of a 
signal peptide at the N-terminus of this precursor sug- 
gests that IAPP may be secreted from pancreatic B- 
cells. 
We recently found that synthetic IAPP inhibited in- 
sulin secretion from isolated rat pancreatic islets, thus, 
IAPP exerts an inhibitory effect on insulin secretion 
[16]. IAPP is also a potent inhibitor of basal and 
insulin-stimulated glycogen synthesis in stripped rat 
soleus muscle [ 171. Since IAPP secretion is regulated by 
glucose, IAPP might be novel regulator for glucose 
homeostasis. Type 2 diabetes mellitus is characterized 
by impaired insulin secretion and insulin resistance in 
skeletal muscle, the chief site of insulin-mediated 
glucose disposal [ 181. Changes in IAPP synthesis and 
secretion perhaps relate to both major traits of this 
form of diabetes mellitus. 
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